Counterfeit medications and fentanyl

JAMA Internal Medicine

Volumn 176, Issue 10, 2016, Pages 1555-1557

  Green, Traci C ^a,b   Gilbert, Michael ^c  

^a BOSTON MEDICAL CENTER   (United States)

^b BROWN UNIVERSITY   (United States)

^c Epidemico Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTIDOTE; COUNTERFEIT DRUG; DIAMORPHINE; ETIZOLAM; FENTANYL; HYDROCODONE; ILLICIT DRUG; NALOXONE; OPIATE;

CASE STUDY; DEATH; DRUG INTOXICATION; DRUG SURVEILLANCE PROGRAM; DRUG TRAFFIC; FOOD AND DRUG ADMINISTRATION; HEALTH SURVEY; HIGH RISK POPULATION; HOSPITAL ADMISSION; HUMAN; LAW ENFORCEMENT; LETTER; POWDER; PRIORITY JOURNAL; RESPIRATION DEPRESSION; TABLET;

COUNTERFEIT DRUGS; FENTANYL;

EID: 84997113246     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2016.4310     Document Type: Letter

References (8)

1. Arens AM, van Wijk XMR, Vo KT, Lynch KL, Wu AHB, Smollin CG. Adverse effects from counterfeit alprazolam tablets [published online August 8, 2016]. JAMA Intern Med. doi:10.1001/jamainternmed.2016.4306.
2. Amlani A, McKee G, Khamis N, Raghukumar G, Tsang E, Buxton JA. Why the FUSS (fentanyl urine screen study)? A cross-sectional survey to characterize an emerging threat to people who use drugs in British Columbia, Canada. Harm Reduct J. 2015;12:54.
3. Hempstead K, Yildirim EO. Supply-side response to declining heroin purity: fentanyl overdose episode in New Jersey. Health Econ. 2014;23(6):688-705.
4. Ciccarone D. Heroin in brown, black and white: structural factors and medical consequences in the US heroin market. Int J Drug Policy. 2009;20(3): 277-282.
5. Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015;23(2):63-75.
6. Walley AY, Xuan Z, Hackman HH, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346:f174.
7. Marshall BD, Milloy MJ, Wood E, Montaner JS, Kerr T. Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. Lancet. 2011;377 (9775):1429-1437.
8. Brunt TM, Nagy C, Bücheli A, et al. Drug testing in Europe: monitoring results of the Trans European Drug Information (TEDI) project. Drug Test Anal. 2016; (Feb):17.